The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Bluebird bio Inc (BLUE) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.09, or 2.35%, to $3.92. The Bluebird bio Inc has recorded 52,332 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress.
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of Bluebird bio Inc is $418.77M. A total of 5.28 million shares were traded on the day, compared to an average of 3.51M shares.
Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, BLUE has seen 0 BUY and 1 SELL insider trades, representing the acquisition of 0 and the disposition of 922 shares. Over the last 12 months, there were 12 BUYs and 9 SELLs from insiders. Insiders purchased 347,003 shares during that period but sold 34,839.
In the most recent transaction, Obenshain Andrew sold 807 shares of BLUE for 3.17 per share on Nov 03. After the transaction, the President and CEO now owns 291,134 company shares. In a previous transaction on Nov 02, Colvin Richard A sold 2,343 shares at 2.98 per share. BLUE shares that Chief Medical Officer owns now total 125,735.
Among the insiders who sold shares, Klima Thomas J disposed of 922 shares on Sep 05 at a per-share price of $3.79. This resulted in the insider holding 132,127 shares of BLUE after the transaction. In another insider transaction, Obenshain Andrew sold 16,929 shares at $3.54 per share on Aug 10. Company shares held by the President and CEO now total 291,941.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for BLUE in the last 3 months, the mean price target is $7.20 with high estimates of $13.00 and low estimates of $3.00. In terms of 52-week highs and lows, BLUE has a high of $8.58 and a low of $2.52.
As of this writing, BLUE has an earnings estimate of -$0.62 per share for the current quarter. EPS was calculated based on a consensus of 13 estimates, with a high estimate of $0.14 per share and a lower estimate of -$1.02. The company reported an EPS of -$0.67 in the last quarter, which was 6.90% higher than expectations of -$0.72.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. BLUE’s latest balance sheet shows that the firm has $396.62M in Cash & Short Term Investments as of fiscal 2021. There were $89.58M in debt and $152.99M in liabilities at the time. Its Book Value Per Share was $2.08, while its Total Shareholder’s Equity was $374.28M.
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BLUE is Buy with a score of 3.67.